We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+13.36%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$1.76B
AUM Growth
+$158M
Cap. Flow
+$12.9M
Cap. Flow %
0.73%
Top 10 Hldgs %
26.37%
Holding
139
New
12
Increased
27
Reduced
23
Closed
3

Top Buys

Rank Stock Value
1
ELLI
Ellie Mae Inc
ELLI
+$22.2M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$21.9M
3
ASND icon
Ascendis Pharma A/S
ASND
+$16.2M
4
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$13.2M
5
FIVN icon
FIVE9
FIVN
+$12.5M

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$19M
2
BLUE
bluebird bio
BLUE
+$17M
3
SPLK
Splunk Inc
SPLK
+$10.6M
4
PFPT
Proofpoint, Inc.
PFPT
+$9.51M
5
KITE
Kite Pharma, Inc.
KITE
+$8.81M

Sector Composition

Rank Sector Weight
1 Healthcare 38.21%
2 Technology 13.87%
3 Consumer Discretionary 13.68%
4 Industrials 7.76%
5 Utilities 4.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XPO icon
1
XPO
XPO
$23.4B
$59.9M 3.4%
2,555,992
– –
BLUE
2
DELISTED
bluebird bio
BLUE
$56.6M 3.21%
31,806
-12,175
-28% -$17M
MIC
3
DELISTED
Macquarie Infrastructure Holdings, LLC
MIC
$52.8M 2.99%
731,100
+3,500
+0.5% +$261K
ABBV icon
4
AbbVie
ABBV
$455B
$49.3M 2.79%
554,500
-3,000
-0.5% -$228K
LOW icon
5
Lowe's Companies
LOW
$118B
$45.2M 2.56%
565,000
– –
ASND icon
6
Ascendis Pharma A/S
ASND
$16.5B
$43.7M 2.47%
1,204,540
+564,540
+88% +$16.2M
LRCX icon
7
Lam Research
LRCX
$372B
$42M 2.38%
2,270,000
– –
CELG
8
DELISTED
Celgene Corp
CELG
$40M 2.27%
274,300
-31,000
-10% -$4.22M
W icon
9
Wayfair
W
$11.9B
$38.1M 2.16%
565,000
– –
WBC
10
DELISTED
WABCO HOLDINGS INC.
WBC
$37.8M 2.14%
255,600
– –
STKL
11
DELISTED
SunOpta
STKL
$33.8M 1.92%
3,887,000
– –
TTD icon
12
Trade Desk
TTD
$8.59B
$33.5M 1.9%
5,440,000
+540,000
+11% +$2.92M
AVXS
13
DELISTED
AveXis, Inc. Common Stock
AVXS
$32.8M 1.86%
339,529
– –
MGA icon
14
Magna International
MGA
$19B
$32.5M 1.84%
608,500
+4,000
+0.7% +$194K
XIFR
15
XPLR Infrastructure LP
XIFR
$1.12B
$31.9M 1.81%
792,000
-6,000
-0.8% -$239K
LEA icon
16
Lear
LEA
$7.33B
$31.8M 1.8%
184,000
– –
CCI icon
17
Crown Castle
CCI
$33.4B
$30.7M 1.74%
307,000
-500
-0.2% -$51.1K
STLD icon
18
Steel Dynamics
STLD
$36.2B
$30M 1.7%
871,000
-79,000
-8% -$2.77M
ASML icon
19
ASML
ASML
$634B
$29.4M 1.67%
172,000
-28,000
-14% -$4.29M
WCN
20
Waste Connections
WCN
$41.9B
$29.4M 1.67%
420,000
– –
ONCE
21
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$28.9M 1.64%
324,000
+174,000
+116% +$13.2M
SGEN
22
DELISTED
Seagen Inc. Common Stock
SGEN
$28.6M 1.62%
525,000
– –
INST
23
DELISTED
Instructure, Inc.
INST
$27.9M 1.58%
842,000
+172,000
+26% +$5.31M
OPLN
24
Openlane
OPLN
$4.29B
$27.5M 1.56%
1,524,434
– –
VRTX icon
25
Vertex Pharmaceuticals
VRTX
$122B
$27.4M 1.55%
180,000
+145,400
+420% +$21.9M
1
2 3 4 5

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q3 2017 Portfolio in Review

As of Q3 2017, Eventide Asset Management held 139 positions worth $1.76B, up 9.9% from $1.61B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Eventide Asset Management's Q3 2017 filing shows 12 new, 27 increased, 23 reduced and 3 closed positions. Its largest new stake was Ellie Mae Inc: 242,000 shares worth $19.9M. The largest sale was Loxo Oncology, Inc, an estimated $19M.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 35% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Eventide Asset Management's largest Q3 2017 buy was Ellie Mae Inc: 242,000 shares worth $19.9M.
  • Eventide Asset Management added most to Vertex Pharmaceuticals in Q3 2017, an estimated $21.9M increase.
  • Eventide Asset Management's biggest Q3 2017 reduction was Loxo Oncology, Inc, cutting an estimated $19M.
  • Eventide Asset Management fully exited Kite Pharma, Inc. in Q3 2017, selling an estimated $8.81M.
  • Eventide Asset Management's ten largest holdings make up 26% of its $1.76B portfolio in Q3 2017.
  • Eventide Asset Management opened 12 new positions and closed 3 in Q3 2017.
  • Eventide Asset Management's portfolio value rose 9.9% quarter-over-quarter to $1.76B.

Based on Eventide Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.